Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
14
ESPR Quote, Financials, Valuation and Earnings
Last price:
$1.70
Seasonality move
:
3.95%
Day range:
$1.60 - $1.72
52-week range:
$1.47 - $3.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.98x
P/B ratio:
--
Volume:
5M
Avg. volume:
3.7M
1-year change:
-19.91%
Market cap:
$334.4M
Revenue:
$332.3M
EPS (TTM):
-$0.25
Analysts' Opinion
-
Consensus RatingEsperion Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.63, Esperion Therapeutics has an estimated upside of 292.38% from its current price of $1.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.05 representing -21.3% downside risk from its current price of $1.69.
Fair Value
-
According to the consensus of 5 analysts, Esperion Therapeutics has 292.38% upside to fair value with a price target of $6.63 per share.
ESPR vs. S&P 500
-
Over the past 5 trading days, Esperion Therapeutics has overperformed the S&P 500 by 12.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Esperion Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Esperion Therapeutics has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Esperion Therapeutics reported revenues of $69.1M.
Earnings Growth
-
Esperion Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Esperion Therapeutics reported earnings per share of -$0.11.
Enterprise value:
481.9M
EV / Invested capital:
-5.00x
Price / LTM sales:
0.98x
EV / EBIT:
64.20x
EV / Revenue:
1.45x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-20.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
63.67x
Gross Profit (TTM):
$263.7M
Return On Assets:
-16.28%
Net Income Margin (TTM):
-15.57%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-6.4%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $75.5M | $116.3M | $332.3M | $32.3M | $69.1M | |
| Gross Profit | $48.5M | $73.1M | $263.7M | $20.8M | $43.5M | |
| Operating Income | -$179.5M | -$155.6M | $54.4M | -$42.4M | -$4.4M | |
| EBITDA | -$176.3M | -$150.1M | $7.6M | -$41.3M | -$4.9M | |
| Diluted EPS | -$3.55 | -$2.12 | -$0.25 | -$0.50 | -$0.11 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $345.9M | $329M | $246.7M | $201.1M | $338M | |
| Total Assets | $353.3M | $381.6M | $247.9M | $205.8M | $343.8M | |
| Current Liabilities | $94.1M | $73.4M | $92.3M | $156.2M | $246.2M | |
| Total Liabilities | $449.4M | $578.5M | $571.7M | $660.8M | $732.5M | |
| Total Equity | -$96.1M | -$196.9M | -$323.8M | -$455M | -$388.7M | |
| Total Debt | $179.4M | $258.3M | $259.9M | $261.6M | $292.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$174.8M | -$135.5M | -$23.7M | -$37.1M | -$35M | |
| Cash From Investing | $8.1M | $42.5M | -$317K | -- | -- | |
| Cash From Financing | $32.6M | $50.5M | $86.5M | $4.5M | $35M | |
| Free Cash Flow | -$174.8M | -$135.5M | -$24M | -$37.1M | -$35M | |
ESPR
Sector
Market Cap
$334.4M
$39.2M
Price % of 52-Week High
42.89%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
-22.61%
-0.81%
1-Year Price Total Return
-19.91%
-38.63%
Beta (5-Year)
1.042
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.58
200-day SMA
Sell
Level
$2.13
Bollinger Bands (100)
Sell
Level
1.7 - 2.6
Chaikin Money Flow
Buy
Level
1.3M
20-day SMA
Buy
Level
$1.64
Relative Strength Index (RSI14)
Sell
Level
49.77
ADX Line
Buy
Level
13.78
Williams %R
Neutral
Level
-43.5897
50-day SMA
Sell
Level
$1.86
MACD (12, 26)
Buy
Level
0.23
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
2.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.8074)
Sell
CA Score
(Annual)
Level (-9.2106)
Sell
Beneish M-Score
(Annual)
Level (-1.4172)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (12.7673)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Stock Forecast FAQ
In the current month, ESPR has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ESPR average analyst price target in the past 3 months is $6.63.
-
Where Will Esperion Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Esperion Therapeutics share price will rise to $6.63 per share over the next 12 months.
-
What Do Analysts Say About Esperion Therapeutics?
Analysts are divided on their view about Esperion Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Esperion Therapeutics is a Sell and believe this share price will drop from its current level to $2.05.
-
What Is Esperion Therapeutics's Price Target?
The price target for Esperion Therapeutics over the next 1-year time period is forecast to be $6.63 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ESPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Esperion Therapeutics is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ESPR?
You can purchase shares of Esperion Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Esperion Therapeutics shares.
-
What Is The Esperion Therapeutics Share Price Today?
Esperion Therapeutics was last trading at $1.70 per share. This represents the most recent stock quote for Esperion Therapeutics. Yesterday, Esperion Therapeutics closed at $1.69 per share.
-
How To Buy Esperion Therapeutics Stock Online?
In order to purchase Esperion Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
